Covaxin
Covaxin News
COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
The company has already conducted trials in the age group of 2-18 for two doses of Covaxin
Health
Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA
Following an inspection of the Bharat Biotech premises on 14 March for Covaxin's EUL, WHO announced the suspension of the vaccine's supply owing to deficiencies in good manufacturing practices
Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12
The DCGI has also given restricted emergency use authorisation to Covaxin, manufactured by Hyderabad based pharmaceutical company - Bharat Biotech, for children between 6 and 12 years
DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years
Bharat Biotech has been asked to submit safety data alongwith the data on adverse event with due analysis, every 15 days for the first two months and after that monthly data for up to five months
Adar Poonawalla warns against return to business-as-usual approach
He pointed out that there is rising vaccine fatigue among the public as the main reason for the low off-take of the vaccines even after the firm has massively slashed the price from Rs 600 to Rs 225 a dose
Health
DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group
India is currently administering two COVID-19 vaccines for children above 12
Health
What we know about COVID-19 XE variant and how to protect ourselves from it
COVID-19 XE variant: With coronavirus is continuously mutating, the spread of new variants is not surprising
Over 9,500 precaution doses of COVID-19 vaccine given on first day, says Centre
India began administering the third dose of the coronavirus vaccine to all aged above 18 years at private vaccination centres on Sunday
Health
Covishield, Covaxin prices for private hospitals reduced to Rs 225 day before booster rollout for above 18 begins
While a dose of Serum Institute's Covshield was priced at Rs 600, a dose of Bharat Biotech's Covaxin used to cost Rs 1,200
Health
High immune response to COVID variants in breakthrough cases after two Covaxin jabs: ICMR study
The study highlights the significance of administering a booster dose or precaution dose of COVID vaccine as it provides better protection against the disease, said Dr Pragya Yadav, a senior scientist at NIV Pune and the lead investigator of the study
WHO suspends Bharat Biotech's Covaxin supply for UN procurement agencies citing 'deficiencies'
The international health body, however, maintained that data available on India’s first indigenous COVID-19 vaccine indicated that it was effective and there were no safety concerns
Usage of masks should be relaxed among children say experts as skin infection risk increased
Also, as the benefit of using masks is low when the virus circulation is limited, experts feel the central government should remove the compulsion for kids.
Why India's vaccine advisory body recommends reducing second-dose gap for Covishield
The National Technical Advisory Group on Immunisation has recommended that the gap between the first and second dose of Covishield should be reduced to eight to 16 weeks, from the current gap of 12 to 16
Covaxin granted emergency use listing in 13 countries, says Centre
According to the WHO, emergency use listing procedure assesses the suitability of new health products during public health emergencies
SII asks Centre to reduce gap between second and precaution COVID-19 dose; what is the global mandate for booster shot
The current gap between the two doses is nine months. The Centre had revised the guidelines for officials on election duty who can now be vaccinated 90 days after their second dose
Intranasal vaccines: What they are, how they can help against COVID-19
Bharat Biotech has received approval for Phase 3 clinical trials of its intranasal coronavirus booster dose from the Drugs Controller General of India (DCGI)
COVID-19: PM Modi congratulates citizens as India successfully vaccinates 75% of its adult population
The Union health ministry said more than 164.36 crore vaccines have been provided to states and Union territories and more than 12.43 crore unutilised vaccines are still available with them
How conditional market authorisation to Covishield and Covaxin will change India’s COVID-19 vaccine drive
Highly-placed sources have said that the conditional market authorisation will now allow the two vaccines to be made available at private hospitals and clinics at pre-decided costs
COVID-19: Regular market approval granted for Covishield, Covaxin for use in adult population
Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting besides recording all vaccinations done within the country on the CoWIN platform, the sources said
Each dose of Covishield, Covaxin likely to be capped at Rs 275 after getting regular market approval
As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities, the prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the country